会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 82. 发明申请
    • METHOD FOR DETERMINING THE CONTENT OF A LIGAND IN A SAMPLE (ALTERNATIVES)
    • 确定样品中配体含量的方法(替代方法)
    • WO2013151464A3
    • 2013-12-12
    • PCT/RU2013000268
    • 2013-03-29
    • NIKITIN MAXIM PETROVICH
    • NIKITIN MAXIM PETROVICH
    • G01N33/566
    • G01N33/5308G01N33/542G01N33/54313G01N33/54333G01N33/54393G01N33/566G01N2400/00
    • The invention relates to biology and medicine, and specifically to the field of biochemical analyses, and makes it possible to determine the presence of a ligand in a sample qualitatively or quantitatively. The essence of the invention consists in a method for determining the content of molecules of at least one type of ligand in a sample, in which method an agent or a carrier is selected, said agent or carrier having a blockable object which is not capable of specifically interacting with the determinable ligand and which participates directly or indirectly in the production of a detectable signal, wherein three-dimensional blocking or three-dimensional electrostatic blocking of said blockable object governs a change in the detectable signal, on the basis of which a ligand is determined in the sample. The technical result of using the invention consists in increasing the sensitivity of the method to the determinable ligand, in shortening the time for carrying out the analysis, in reducing the quantity of required reagents for carrying out the analysis, in increasing the convenience of carrying out the analysis, and in providing for the possibility of carrying out the analysis in the field as well.
    • 本发明涉及生物学和医学,具体涉及生物化学分析领域,并且可以定性或定量地确定样品中配体的存在。 本发明的实质在于确定样品中至少一种类型配体的分子含量的方法,在该方法中选择药剂或载体,所述药剂或载体具有不能与 特异性地与可确定的配体相互作用,并且其直接或间接参与可检测信号的产生,其中所述可阻断物体的三维阻断或三维静电阻断决定可检测信号的变化,基于该配体,配体 在样本中确定。 使用本发明的技术结果在于增加方法对可测定配体的灵敏度,缩短进行分析的时间,减少进行分析的所需试剂的量,增加实施的便利性 分析以及提供在现场进行分析的可能性。
    • 86. 发明申请
    • ABCG2 TRANSPORTER ASSAY
    • ABCG2运输车测定
    • WO2013128217A1
    • 2013-09-06
    • PCT/HU2013/000021
    • 2013-02-28
    • CELLPHARMA LLC
    • SARKADI, BalázsTELBISZ, Ágnes
    • G01N33/566
    • C12Q1/34G01N33/566
    • The invention relates to membrane preparations for use in an increased sensitivity ABCG2 protein activity assay, said preparations comprising liposomes and one or more bile acid compounds wherein the bile acid compounds reduce the basal ATPase activity in said liposomes. Said membrane preparations can be cell membrane preparations or a membrane protein preparations. The invention also relates to methods for obtaining said membrane preparations, either cell membrane preparations or, preferably, membrane protein preparations comprising a reconstituted, recombinant ABCG2 protein. The invention also relates to kits comprising said membrane preparations as well as uses said kits, membrane preparations or bile acid compounds in high sensitivity ABCG2 protein activity assays.˙
    • 本发明涉及用于增加敏感性ABCG2蛋白活性测定的膜制剂,所述制剂包含脂质体和一种或多种胆汁酸化合物,其中胆汁酸化合物降低所述脂质体中的基础ATP酶活性。 所述膜制剂可以是细胞膜制剂或膜蛋白制剂。 本发明还涉及获得所述膜制备物,细胞膜制剂或优选包含重组的重组ABCG2蛋白的膜蛋白制剂的方法。 本发明还涉及包含所述膜制剂的试剂盒以及在高灵敏度ABCG2蛋白活性测定中使用所述试剂盒,膜制剂或胆汁酸化合物。